Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05396196
Other study ID # IRB0003556
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 25, 2021
Est. completion date May 27, 2021

Study information

Verified date May 2022
Source North Dakota State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Up to 15 participants between the ages of 18-55 will report for two research sessions. Prior to arrival, minimum requirements for being recreationally active or a recreational runner will be confirmed via email using the Pre-Participation Screening form. The first session will require one hour, while the second will require 30 minutes. Maximum amount of time expected is one and a half hours, over two sessions in 48 hours. The 1st and 2nd sessions will be separated by 48 hours. Upon arrival for session 1, informed consent will be obtained along with the following demographic information: age, sex, height, weight, dominant leg, and activity. Participants will then be assessed for trigger points in their dominant side iliotibial band via palpation. Diagnostic criteria for trigger point will be modeled after Travell and Simons: taut band and pain upon palpation. One to four trigger points will be marked on the subject's skin with marker or pen. Pain pressure threshold will be obtained via algometer, using the terminology "Tell me the first moment you experience pain by verbalizing 'now'. Then, three pain pressure threshold readings will be taken per trigger point and then averaged by the researcher. Following, a Visual Analogue Scale for pain will be assessed by asking the question 'On average, on a scale from 0-10 how painful was the pressure?' Kinesiology tape will then be applied to the identified trigger points using the Manual Fascial Glide. The Manual Fascial Glide will be applied with one 'I' strip horizontal to each trigger point. The tape will be anchored adjacent to the marked trigger point, a gentle pressure will be placed on the anchor while applying a lateral glide of the superficial tissue, and adhering the tape in the opposite direction at 30% tension. Pain pressure threshold will be obtained again with the same protocols 10 minutes after the tape is applied. The participant will be asked to wear the tape for 48 hours. Upon arrival for session 2, the application of the tape will be confirmed. Next, a second VAS for pain regarding the previous 48 hours will be completed by the participant. With the participant's choice to continue in the study, a third and fourth measurement of pain pressure threshold will be obtained: one with the tape remaining on, and another 10 minutes after removal of the tape. Again, three pain pressure threshold readings will be taken per trigger point and then averaged by the researcher. Regarding the new Covid-19 protocols for face-to-face research studies, the following protection guidelines will be followed according to the IRB recommendations. All participants will be seen individually, with no other participants in the research area at the same time. Due to the extended interaction, all participants and researchers will be required to wear a face covering, which covers their mouth and nose at all times while in the research area. The researcher will also wear a face covering over nose and mouth at all times in the research area. This study does not include any high exertion exercise which would increase the risk of infection. Physical distancing of 2 meters between the participant and the researcher will be maintained before and after any necessary close contact evaluation or tape application. All equipment (algometer, computer, examination tables, stools/chairs, pens, scissors, adherent spray bottle, hair trimmer) will be disinfected between each participant. Any disposable equipment (isopropyl alcohol pads, tape, or tape paper) will be disposed of immediately after use. The researcher will wash hands before and after each physical interaction with participants according to the CDC guidelines. Ventilation will be considered in the research area by allowing the door to remain open if the participant allows. Finally, the IRB approved COVID-19 screening questions will be presented to the participant before any part of the research study is completed. If any person answers 'yes' to any of the questions, they cannot participate.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date May 27, 2021
Est. primary completion date May 27, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Recreationally active per the American College of Sports Medicine or Recreational runners will have to report at least 10 miles a week for the last three months. Exclusion Criteria: - acute strain or surgery to the knee, quadriceps, or hamstrings - allergy to adhesive - malignancies - cellulitis - skin infection - diabetes - fragile skin

Study Design


Intervention

Device:
Kinesio® Tape
Manual Fascial Glide Application

Locations

Country Name City State
United States North Dakota State University Fargo North Dakota

Sponsors (1)

Lead Sponsor Collaborator
North Dakota State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary with-in subject differences pre- and 10-minute post- tape application measured by pain pressure threshold (N/s2) via algometer 10 minutes
Primary with-in subject differences pre- and 48-hour post- tape application measured by pain pressure threshold (N/s2) via algometer 48 hours
Primary with-in subject differences 10-minute post- and 48-hour post- tape application measured by pain pressure threshold (N/s2) via algometer 48 hours
Primary with-in subject differences 48-hour post- tape application and post- 10- minute tape removal measured by pain pressure threshold (N/s2) via algometer 48 hours
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06029413 - Myo vs. Myofascial Injection for Myofascial Trigger Points N/A
Recruiting NCT04985578 - Effects on Muscle Activity After Dry Needling in Myofascial Trigger Points of the Gastrocnemius Muscles N/A
Completed NCT05546203 - Trigger Point Treatment in Chronic Pelvic Pain N/A
Completed NCT06258070 - Clinical Performance of Therapeutic Use of BTX for Bruxism N/A
Completed NCT04531306 - An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band N/A
Completed NCT03708107 - Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points N/A
Completed NCT02913976 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain N/A
Completed NCT02913963 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point N/A
Completed NCT04719689 - Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis N/A
Recruiting NCT05792111 - Caudal Epidural Steroid and Trigger Point Injection Phase 4
Completed NCT03704311 - Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry N/A
Recruiting NCT05429827 - The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome N/A
Recruiting NCT05151510 - Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department Phase 4
Completed NCT05664165 - The Efficiency of Dry Needling and Cold Spray-stretching Treatments N/A
Completed NCT01250184 - Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Phase 4
Enrolling by invitation NCT03941054 - Myosfascial Trigger-Points and Effects on Neuromuscular Response N/A
Completed NCT04993118 - Integration of Neuromuscular Inhibition Technique On Trapezius Trigger Points. N/A
Completed NCT04851743 - Effects on Neuromuscular Function After Dry Needling in Myofascial Trigger Points in the Gastrocnemius Muscles N/A
Not yet recruiting NCT06338514 - The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome. N/A
Recruiting NCT06013644 - Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome Early Phase 1